Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within XXXX and @entity2841 ( @entity2841 ) as effective first- and second-line treatment of disseminated @entity14 .

@entity1 @entity3432 @entity391 @entity4831 @entity1431 @entity14 @entity490 @entity2841 @entity1487
BACKGROUND/AIMS: In order to improve local and systemic efficacy of chemotherapeutic interventions we have used a combination of high concentrated plus low continuous regional chemotherapy modulated by @entity2841 cytokine in the treatment of inoperable @entity14 . METHODOLOGY: Sixty-six @entity1 with disseminated inoperable @entity14 received continuous intra-arterial chemotherapy with @entity1487 plus @entity2841 short time application plus chemoembolization Melphalan via an angiographically positioned hepatic artery catheter. The regimen consisted of the following steps: On day 1 + 2 1400 mg/m2 @entity1487 administered intra-arterially in a continuous circadian mode, 60 mg/m2 Rescuvolin given i.v. as a 2-hour infusion, 80 micrograms/m2 @entity2841 given i.a. as a 1-hour infusion, day 3 chemoembolization with 25 mg/m2 Melphalan plus @entity4831 and Gelfoam. RESULTS: 66 @entity1 (38 male/28 female) with a median age of 60.4 years and a median Karnofsky index of 87.3 were treated with 299 cycles of immunochemoembolization. Fifty-four percent of these @entity1 had received prior systemic chemotherapy. Side effects were manifested in all @entity1 , mainly upper @entity490 lasting one to four days and grade 1 or 2 @entity391 . Systemic side effects were mild and transient with a very low rate of @entity1431 . Using World Health Organization response criteria, the following responses could be demonstrated @entity3432 .0%, PR 42.4%, MR 24.2%, SD 18.2%, NR 12.1%. Time to progression was 8 months. Median survival has not been reached after an observation time of 28 months. Two-year survival was 66%. There was no statistically significant difference between chemonaive @entity1 and @entity1 pretreated by any kind of systemic therapy. CONCLUSIONS: Repetitive high concentrated regional chemotherapy by use of chemoembolization combined with continuous administered @entity1487 and supplemented with @entity2841 is an effective tool in the therapy of disseminated @entity14 as front line as well as a second-line treatment.
